Monday, 30 January 2012
Friday, 27 January 2012
Thursday, 26 January 2012
"If you can't beat them, join them!" is a proverb often used in politics and war. In this case we use it for a financial strategy chosen by the "commanders" of Roche. Some rumors started to appear in the past weeks, but now Roche comes out with an official bid of (please take a sit) $5.7 billions to acquire Illumina, more precisesly $44.50 per share in cash, an 18 percent premium over Illumina's closing share price of $37.69 yesterday.
Apparenlty Roche started to negotiate silently with Illumina to find a way to reach a deal, but Illumina decided to refuse any kind of offer. Franz Humer, Roche’s chairman, decided, after numerous efforts, to release a public letter to Illumina chief executive and chairman Jay Flatley bemoaning “the lack of any substantive progress in our efforts to negotiate a business combination between Illumina and Roche” and a January 18 letter confirmed a lack of interest by Illumina’s board.
Tuesday, 24 January 2012
Today the MassGenomics blog reports an EXCELLENT survey of the current state of dbSNP written by Dan Koboldt.
Friday, 20 January 2012
Thursday, 19 January 2012
The diffusion of NGS technology has made clear that no one has the ability to analyze in depth all the data produced in large scale WGS or WES projects.
Wednesday, 18 January 2012
Saturday, 14 January 2012
In the other study (A novel retinoblastoma therapy from genomic and epigenetic analyses) investigators sequenced the tumors of four young patients with retinoblastoma, a rare childhood tumor of the retina of the eye. The finding also led investigators to a new treatment target and possible therapy.
Friday, 13 January 2012
NGS techniques are rapidly changing many aspects of the research world. Their wide potential applications are many and probably not all are already known.On the new Nature Biotechnology issue (January 2012), N.D. DeWitt et al describe one of the most challenging and interesting support that NGS techniques can offer in biomedical research: an engagement in the Stem Cell field. “There is an urgent need”, DeWitt says, “to ramp up the efforts to establish stem cell as a leading model system for understanding human biology and disease states.” Several analysis on human iPS cells (hiPSCs) and on human ES cells (hESCs) detected structural and sequence variations under some culture conditions. It is not yet clear if these variations are present in the original cell (for hiPSCs) or if they are due to the process of deriving cells or even to the culture conditions. What is clear is the need to understand what causes the variations and to determine what kind of changes in cellular behaviour these variations lead to.
Thursday, 12 January 2012
Wednesday, 11 January 2012
It comes at no surprise that yesterday also Illumina had a press release introducing the HiSeq 2500, an evolution of their HiSeq 2000 platform that will enable researchers and clinicians to sequence a “Genome in a Day”.
Tuesday, 10 January 2012
This is a big news in the NGS market. Today Life Technologies announced the Ion Proton, an evolution of the Ion Torrent PGM designed to sequence the entire human genome in a day for $1,000.